The abstract is read at the publisher; the summary is JClub's.
DAPSA44 is the best-performing composite instrument for assessing peripheral-arthritis–related disease activity in axial and peripheral spondyloarthritis, with 92% agreement in axSpA and 97% in pSpA.
- Why it matters: Peripheral arthritis is a key domain in axSpA and pSpA, but clinical research needs instruments with adequate measurement properties rather than relying on joint counts alone.
- What they did: Using the OMERACT framework, ASAS combined a systematic literature review, working-group domain/feasibility review, a second review of measurement properties, and analyses of individual patient data from 13 randomized controlled trials.
- The result: Composite measures outperformed single-item joint counts; DAPSA44 showed better construct validity, responsiveness, and clinical trial discrimination, leading ASAS to recommend it for future studies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.